Clinical trials
Disease clinical trials
Below are recruiting disease clinical trials, each written for real people, not researchers. We’re tracking 9,506 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07725939RecruitingPhase 2
Study of Galvokimig for moderate-to-severe COPD with chronic bronchitis
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
Boerne, TexasAges 40–80 - NCT06164730RecruitingPhase 1
Study of VERVE-102 for high cholesterol or early heart disease
This trial tests a new medicine called VERVE-102 for people with a specific type of high cholesterol (HeFH) or early coronary artery disease. It aims to see if it can help lower cholesterol levels.
Dothan, AlabamaAges 18–70 - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Chandler, ArizonaAges 18–70 - NCT00001215Enrolling by invitation
Understanding Genetic Lysosomal Storage Disorders
This study aims to understand genetic factors in lysosomal storage disorders—rare conditions where the body cannot break down certain substances. Researchers will collect information from patients with these disorders, their family members, and healthy volunteers to learn how these diseases develop and affect people over time.
Bethesda, MarylandAges 1 week–110 years - NCT06305624Recruiting
Smartphone app to help people with alcohol-related liver disease stop drinking
This trial tests whether a smartphone program can help people with alcohol-related liver disease reduce or stop drinking. If you have liver disease related to alcohol and have used alcohol in the past 6 months, this app-based support may be for you.
Lansing, MichiganAges 18 years+ - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85 - NCT06980649RecruitingPhase 1
Study of BHV-1300 in Graves' Disease
This trial tests a new treatment called BHV-1300 for people with Graves' disease. It aims to see if the drug is safe and works well. If you have Graves' disease confirmed by blood tests, you may be able to join.
South Gate, CaliforniaAges 18–65 - NCT07606339Recruiting
Guselkumab for moderate-to-severe Crohn's or ulcerative colitis
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
ViennaAges 18 years+ - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT07207122Recruiting
Focused ultrasound for Parkinson's cognitive symptoms
This trial tests whether a non-invasive ultrasound treatment, called transcranial focused ultrasound stimulation (tFUS), can improve movement and thinking in people with Parkinson's disease. It may be an option for those whose symptoms are not well controlled by medication alone.
Tucson, ArizonaAges 22–80 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07632755Recruiting
Memory Training Using Movement for Early Alzheimer's Disease
This study tests whether learning memory strategies through physical movement and motor activities can help people with early Alzheimer's disease improve their memory. Researchers will compare people with early Alzheimer's to healthy older adults to see if this approach is effective.
GrenobleAges 60 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Chandler, ArizonaAges 18 years+ - NCT07736872Recruiting
Sleep apnea screening in diverse groups
This study is screening people from different backgrounds for obstructive sleep apnea (a condition where breathing stops and starts during sleep). It uses a sleep test and questionnaires to see if you might have it.
Guangzhou, GuangdongAges 18–80 - NCT07720349Recruiting
Digital follow-up for heart disease patients
This trial tests a digital tool to monitor patients after a heart attack or stent procedure, using a smartphone or tablet to improve long-term care.
ArendalAges 18 years+ - NCT07737340Recruiting
Metabolic liver disease in new HIV patients
This study looks at liver health in people newly diagnosed with HIV, before they start HIV treatment. It aims to understand early changes in the liver related to metabolism.
Ankara, AnkaraAges 18 years+ - NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Birmingham, AlabamaAges 18 years+ - NCT00246857Recruiting
Screening study for inherited immune system conditions
This study screens people who may have an inherited immune system condition (like problems with immune cell growth or death) and their blood relatives. The goal is to understand the condition better by collecting blood samples for testing.
Bethesda, MarylandAges 1 month–100 years - NCT07224776RecruitingPhase 1
Sparsentan for proteinuria from VEGF inhibitor cancer treatment
This trial tests if sparsentan can reduce high levels of protein in the urine caused by VEGF signaling pathway inhibitors (VSPIs), a type of cancer treatment. It may help protect kidney function during cancer therapy.
Boston, MassachusettsAges 18 years+ - NCT07161544RecruitingPhase 1/Phase 2
Gene therapy for Stargardt disease
This trial tests a new gene therapy, AAVB-039, for people with Stargardt disease caused by a specific gene mutation. The treatment is given during eye surgery and aims to slow or stop vision loss.
Phoenix, ArizonaAges 8–55 - NCT07082725RecruitingPhase 3
Study of oral nizubaglustat for Niemann-Pick type C
This study tests an oral medication called nizubaglustat for people with Niemann-Pick type C disease who cannot take or are not satisfied with the current treatment miglustat. It aims to see if the drug can help with symptoms like coordination and movement problems.
Oakland, CaliforniaAges 4 years+ - NCT07471438Recruiting
MRI comparison for Crohn's disease activity in the ileum
This trial compares two types of MRI scans to see how well they detect inflammation in the small intestine of people with Crohn's disease. It aims to find the best way to assess disease activity without invasive procedures.
AmiensAges Any age - NCT05503225RecruitingPhase 2
Colchicine for narrowed brain arteries after recent stroke
This Phase 2 trial tests whether colchicine can help people with significant narrowing in brain arteries (from atherosclerosis) after a recent stroke or “mini-stroke.” It aims to reduce the risk related to this condition during the early period after symptoms begin.
Hong KongAges 40–80
Hear when a new Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for disease?
- Yes. Clin2 currently lists 9,506 recruiting disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.